Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Open Access Gateway

No Association between Vitiligo and Obesity: A Case-Control Study

Dragoni F.a · Conti R.a · Cazzaniga S.b · Colucci R.a · Pisaneschi L.a · Naldi L.b · Moretti S.a

Author affiliations

aDepartment of Surgery and Translational Medicine, Section of Dermatology, University of Florence, Florence, and bGISED Study Centre, Ospedali Riuniti, Bergamo, Italy

Corresponding Author

Dr. Federica Dragoni

Department of Surgery and Translational Medicine

Section of Dermatology, University of Florence

Viale Michelangiolo 41, IT-50125 Florence (Italy)

E-Mail federicadragoni@yahoo.it

Related Articles for ""

Med Princ Pract 2017;26:421-426

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Objective: The purpose of this study was to investigate the relationship between vitiligo and body mass index (BMI) to assess the possible association between vitiligo and obesity. Subjects and Methods: This was a case-control study on a total of 400 participants, i.e., 200 patients with vitiligo and 200 healthy volunteers. Medical assessments were performed by dermatologists using the modified Vitiligo European Task Force form. The height and weight of all of the participants were measured and used to calculate the BMI. Data were analyzed using multivariate logistic regression models. Adjustment for age and gender was carried out preliminarily in the case-control analysis, whereas a forward stepwise selection algorithm was used to assess which independent factors were associated with a BMI ≥30 or a BMI ≤18.5. Results: Comparison of the vitiligo and control groups revealed the absence of a significant association. The multivariate analysis of factors associated with a high BMI (≥30) in vitiligo patients showed a significant association between a high BMI and a sudden onset of vitiligo (p = 0.021; OR = 3.83; 95% CI 1.22-11.99) and the presence of inflammation and pruritus (p = 0.031; OR = 3.26; 95% CI 1.11-9.57). No significant association was observed in the analysis of factors associated with a low BMI (≤18.5) in vitiligo patients. Conclusion: In this study, vitiligo did not appear to be associated with a high BMI; obesity might not be a risk factor for vitiligo, in contrast to most autoimmune diseases which are significantly associated with obesity.

© 2017 The Author(s) Published by S. Karger AG, Basel


  1. Ezzedine K, Eleftheriadou V, Whitton M, et al: Vitiligo. Lancet 2015;386:74-84.
  2. Conti R, Colucci R, Arunachalam M, et al: Hair and scalp disorders in a Tuscan pediatric dermatological outpatient clinic: a clinical and epidemiological evaluation. Med Princ Pract 2016;25:67-71.
  3. Ongenae K, Van Geel N, Naeyaert JM: Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003;16:90-100.
  4. Colucci R, Dragoni F, Moretti S: Oxidative stress and immune system in vitiligo and thyroid diseases. Oxid Med Cell Longev 2015;2015:631927.
  5. Al-Herz A, Al-Awadhi A, Saleh K, et al: Low prevalence of modules in rheumatoid arthritis patients in Kuwait: a description and a comparison of patients from the Kuwait Registry for Rheumatic Diseases. Med Princ Pract 2017;26:152-156.
  6. Procaccini C, Carbone F, Galgani M, et al: Obesity and susceptibility to autoimmune diseases. Expert Rev Clin Immunol 2011;7:287-294.
  7. Versini M, Jeandel PY, Rosenthal E, et al: Obesity in autoimmune diseases: not a passive bystander. Autoimmun Rev 2014;13:981-1000.
  8. Winsz-Szczotka K, Kuznik-Trocha K, Komosinska-Vassev K, et al: Relationship between adiponectin, leptin, IGF-1 and total lipid peroxides plasma concentrations in patients with systemic sclerosis: possible role in disease development. Int J Rheum Dis 2016;19:706-714.
  9. Arunachalam M, Dragoni F, Colucci R, et al: Non-segmental vitiligo and psoriasis comorbidity - a case-control study in Italian patients. J Eur Acad Dermatol Venereol 2014;28:433-437.
  10. Bulló M, García-Lorda P, Megias I, et al: Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res 2003;11:525-531.
  11. Procaccini C, Pucino V, Mantzoros CS, et al: Leptin in autoimmune diseases. Metabolism 2015;64:92-104.
  12. Fidan-Yaylali G, Yaylali YT, Erdogan Ç, et al: The association between central adiposity and autonomic dysfunction in obesity. Med Princ Pract 2016;25:442-448.
  13. Bagir GS, Bakiner OS, Bozkirli E, et al: Body mass index below obesity threshold implies similar cardiovascular risk among various polycystic ovary syndrome phenotypes. Med Princ Pract 2016;25:61-66.
  14. Camara-Lemarroy CR, Salas-Alanis JC: The role of tumor necrosis factor-α in the pathogenesis of vitiligo. Am J Clin Dermatol 2013;14:343-350.
  15. Moretti S, Spallanzani A, Amato L, et al: New insights into the pathogenesis of vitiligo: Imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res 2002;15:87-92.
  16. Singh S, Singh U, Pandey SS: Serum concentration of IL-6, IL-2, TNF-α, and IFNγ in vitiligo patients. Indian J Dermatol 2012;57:12-14.
  17. Yu HS, Chang KL, Yu CL, et al: Alterations in IL-6, IL-8, GM-CSF, TNF-alpha, and IFN-gamma release by peripheral mononuclear cells in patients with active vitiligo. J Invest Dermatol 1997;108:527-529.
  18. Zhou L, Shi YL, Li K, et al: Increased circulating Th17 cells and elevated serum levels of TGF-beta and IL-21 are correlated with human non-segmental vitiligo development. Pigment Cell Melanoma Res 2015;28:324-329.
  19. Karadag AS, Tutal E, Ertugrul DT: Insulin resistance is increased in patients with vitiligo. Acta Derm Venereol 2011;9:541-544.
  20. Rodríguez-Martín M, de Paz NM, Mehtani P, et al: Patients with vitiligo present fewer cardiovascular risk factors: results from a case-control study. J Eur Acad Dermatol Venereol 2013;27:124-125.
  21. Moretti S, Arunachalam M, Colucci R, et al: Autoimmune markers in vitiligo patients appear correlated with obsession and phobia. J Eur Acad Dermatol Venereol 2012;26:861-867.
  22. Taïeb A, Picardo M; VETF Members: The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 2007;20:27-35.
  23. Makki K, Froguel P, Wolowczuk I: Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines. ISRN Inflamm 2013;2013:139239.
  24. Vousden KH, Prives C: Blinded by the light: the growing complexity of p53. Cell 2009;137:413-431.
  25. Schallreuter KU, Behrens-Williams S, Khaliq TP, et al: Increased epidermal functioning wild-type p53 expression in vitiligo. Exp Dermatol 2003;12:268-277.
  26. Salem MM, Shalbaf M, Gibbons NC, et al: Enhanced DNA binding capacity on up-regulated epidermal wild-type p53 in vitiligo by H2O2-mediated oxidation: a possible repair mechanism for DNA damage. FASEB J 2009;23:3790-3807.
  27. Molchadsky A, Ezra O, Amendola PG, et al: p53 is required for brown adipogenic differentiation and has a protective role against diet-induced obesity. Cell Death Differ 2013;20:774-783.
  28. Choy L, Derynck R: Transforming growth factor-beta inhibits adipocyte differentiation by Smad3 interacting with CCAAT/enhancer-binding protein (C/EBP) and repressing C/EBP transactivation function. J Biol Chem 2003;278:9609-9619.
  29. Ali AT, Hochfeld WE, Myburgh R, et al: Adipocyte and adipogenesis. Eur J Cell Biol 2013;92:229-236.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: March 05, 2017
Accepted: September 12, 2017
Published online: September 12, 2017
Issue release date: December 2017

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 3

ISSN: 1011-7571 (Print)
eISSN: 1423-0151 (Online)

For additional information: https://www.karger.com/MPP

Open Access License / Drug Dosage / Disclaimer

This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.